Related Research Articles
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel,Switzerland. Consistently ranked in the global top five,Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋkoꜜːɡʲoː] is a Japanese multinational pharmaceutical company,with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology,rare diseases,neuroscience,gastroenterology,plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku,Osaka,and it has an office in Nihonbashi,Chuo,Tokyo. In January 2012,Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015,Christophe Weber was appointed as the CEO and president of Takeda.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide),which is used in the treatment of multiple myeloma,and also in certain anemias. The company is incorporated in Delaware,headquartered in Summit,New Jersey,and a subsidiary of Bristol Myers Squibb (BMS).
Joseph Jimenez is the former CEO of the American Swiss pharmaceutical company Novartis.
Alex Gorsky is an American businessman. He is the former Chairman and Chief Executive Officer of Johnson &Johnson. Gorsky stepped down as CEO of Johnson &Johnson in January 2022 and was succeeded by Joaquin Duato. He was the seventh person who served as the company's chairman and chief executive officer since it became a publicly traded company in 1944.
Marc de Garidel is a French businessman. He is the non-executive chairman of the pharmaceutical company Ipsen and advises Mayroy,the Ipsen controlling holding company.
Alnylam Pharmaceuticals,Inc. is an American biopharmaceutical company focused on the discovery,development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge,Massachusetts. In 2016,Forbes included the company on its "100 Most Innovative Growth Companies" list.
Bruce Dale Broussard is President and chief executive officer and president of Humana,a healthcare company with headquarters in Louisville,Kentucky.
Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals,from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck &Co. for $9.5 billion.
Vasant "Vas" Narasimhan is an Indian-American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He worked in McKinsey &Co and Sandoz before joining Novartis.
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel,potentially curative therapeutics leveraging CRISPR-based technologies. The company’s in vivo programs use intravenously administered CRISPR as the therapy,in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
C. Glenn Begley is a hematologist and oncologist who was the CEO of BioCurate,an Australia-based joint venture between the University of Melbourne and Monash University that was launched in 2016. Previously,he worked at the California-based biotech company Akriveia Therapeutics as their chief scientific officer. His other previous positions include global head of hematology and oncology research at Amgen,senior vice president and chief scientific officer at TetraLogic Pharmaceuticals,and executive director of the Western Australian Institute of Medical Research.
Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals,a biotechnology company based in Boston,Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.
IFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.
Paul Hudson is a British businessman,and the chief executive (CEO) of Sanofi,the world's fifth largest pharmaceutical company by prescription drug sales.
Elcin Barker Ergun is a business leader in the pharmaceutical industry. In September 2019 she was appointed Chief Executive Officer and Member of the Board of Directors of the Italian company Menarini Group.
John Maraganore is an American scientist,entrepreneur,and life sciences industry leader.
Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics.
Richard B. Gaynor is an American physician specializing in hematology-oncology,educator,drug developer,and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade,and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB,IκB kinase,and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies,with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half,he worked at Eli Lilly and Company,where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020,when he became the President of BioNTech US,both pharmaceutical companies headquartered in Cambridge,MA. His honors include being elected a member of the American Society for Clinical Investigation,and the Association of American Physicians.
References
- ↑ "David Meek biography". Bloomberg. Retrieved 2016-08-16.
- ↑ "Executive Profile: David Meek's mandate is simple: Build Cambridge's next cancer-drug giant". Boston Business Journal. Retrieved 2022-09-25.
- ↑ "David Meek, CEO Novartis Canada". Canada's research. Retrieved 2008-10-16.
- ↑ "Endocyte Appoints David Meek to Newly Created Position of Chief Commercial Officer". Endocyte. Retrieved 2012-07-26.
- ↑ "David Meek leaves Novartis to join Endocyte as first chief commercial officer". PMlive. 30 July 2012. Retrieved 2012-07-30.
- ↑ "Endocyte appoints Novartis vet David Meek as chief commercial officer". Center watch. Retrieved 2012-07-29.
- ↑ "Baxalta's oncology chief builds out company's third leg". Medical marketing and media – Larry Dobrow. 18 December 2015. Retrieved 2015-12-18.
- ↑ "Baxalta: The fastest-growing oncology drug 'startup' in Kendall Square". Boston business journal. Retrieved 2015-12-11.
- ↑ "David Meek, president of oncology division of Baxalta". Baxalta. Retrieved 2015-07-11.
- ↑ "Ipsen Names David Meek CEO". Nasdaq. Retrieved 2016-07-11.
- ↑ "David Meek appointed CEO Ipsen". Pharma Forum – Richard Staines. Retrieved 2016-08-16.
- ↑ "After Baxalta-Shire merger, David Meek lands CEO job at leaderless Ipsen". Fiercebiotech – Ben Adams. Retrieved 2016-07-11.
- ↑ "David Meek appointed as Chief Executive Officer of Ipsen" (Press release). Business Wire. 11 July 2016. Retrieved 2016-08-16.
- ↑ "Ex-Baxalta exec David Meek takes Paris-based helm for Ipsen". Endpoints news – John Carroll. Retrieved 2016-07-11.
- ↑ "Ipsen Announces Departure of David Meek as Chief Executive Officer". Ipsen. Retrieved 2022-09-25.
- ↑ "FerGene Appoints David Meek Chief Executive Office". FerGene. Retrieved 2022-09-25.
- ↑ "An Interview With Brad Hartman From FerGene". Medical Science Liaison Society. 17 March 2020. Retrieved 2022-09-25.
- ↑ "Fresh off FerGene's meltdown, David Meek takes over at Mirati with lead KRAS drug racing to an approval". Endpoint News. Retrieved 2022-09-25.
- ↑ "Mirati Therapeutics Appoints David Meek as Chief Executive Officer". Mirati Therapeutics. Retrieved 2022-09-25.